Life science manufacturers need guidance on how to stay on top of the latest state policy trends impacting orphan drug development as recent policy changes are challenging bipartisan support for rare disease patients. ADVI helped manufacturers identify state laws and proposed legislation that offer opportunities to engage policymakers on orphan drug development and rare diseases. We provided analysis to prioritize state opportunities, also based on identifying state policy risks.

The Challenge

Recent policy changes undermine the bipartisan support for rare disease patients and create additional barriers to orphan drug development. Life science manufacturers need insights into opportunities to engage policymakers, patients, and other stakeholders to improve their engagement and advocacy of orphan drug development. Manufacturers dedicated to orphan drugs development sought to determine how their stakeholder advocacy and government affairs efforts could be best utilized to mitigate risk and engage with state policymakers.

The Strategy

ADVI worked with manufacturers to identify state laws as well as proposed legislation that could provide the opportunity to engage state policymakers on the importance of orphan drug development and the challenges of rare disease patients. We then provided further analysis to prioritize these state opportunities based on the existing and potential risks that may impact the manufacturer, as state policymakers consider price controls and other price setting proposals.

The Results

ADVI’s clients used the information in their strategy planning as they continued to educate and engage policymakers on the importance of orphan drug development. ADVI received positive feedback that our legislative tracking and analysis was further expanded to include 15 other policy priorities.

Learn More

Stay ahead of the curve and learn more about the 16 state policy areas we are tracking, as well as additional custom tracking to meet client needs, by getting in touch with our federal and state policy team.